Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million ...

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable ...

The global Skincare Supplement Market is experiencing significant expansion, driven by increasing consumer awareness regarding skin health and the ...